Experts discuss groundbreaking therapies in dermatology at Maui Derm 2026, addressing complex skin diseases and enhancing patient care with innovative treatments.

About 1.8 million people used one or more of the 15 drugs through Medicare Part D or Part B between November 2024 and October 2025, the CMS said. The batch of 15 meds accounted for about $27 billion ...

The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...

It is an illness that affects one in 2,000 people ...

In more severe cases, large areas of the body can be affected, especially after swimming in cold water or spending a long time outdoors. This leads to uncontrollable itchiness, as well as facial ...

Sanofi and Regeneron’s Dupixent (dupilumab) has received positive final draft guidance from the National Institute for Health ...

A simple skin itch spiraled into chronic sneezing, sleepless nights, and daily medication. After years of treatment, she ...

Growth stocks, especially in the biotech sector, often have the potential to deliver outsized returns. A breakthrough in ...

HYDRINITY Accelerated Skin Science, the fastest-growing professional skincare brand in the U.S., is pleased to announce a new partnership with Monti Medical Corp S.A. of Costa Rica. Founded in 2002, ...

LEO Pharma A/S, a global leader in medical dermatology, today announced it will present 23 scientific posters at Maui Derm ...

Regeneron Pharmaceuticals, Inc. nears a key earnings report after a strong JPM Healthcare update. Click here to find out why ...

A 58-year-old woman was admitted to the hospital 3 weeks after lumbar surgery because of diplopia and fever. Left leg pain and a rash had preceded the fever and diplopia. A diagnosis was made.